eFFECTOR Therapeutics Garners $16,000,000 Series B Financing Round

  • Feed Type
  • Date
    2/19/2016
  • Company Name
    eFFECTOR Therapeutics
  • Mailing Address
    11180 Roselle Street San Diego, CA 92121 USA
  • Company Description
    eFFECTOR Therapeutics is pioneering a new class of small molecule drugs that act by selectively regulating translation, also known as protein synthesis. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention.
  • Website
    http://www.effector.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $16,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    These developments further position eFFECTOR to pursue comprehensive clinical development of its lead product candidate, eFT508, a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, across multiple tumor types. The funds will also be used to advance the company’s discovery pipeline addressing additional targets.
  • M&A Terms
  • Venture Investor
    Sectoral Asset Management
  • Venture Investor
    Undisclosed

Trending on Xconomy